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Abstract
Sub-micron phase-change contrast agents consist of a liquid perfluo ocarbon core that can be 
vaporized by ultrasound (acoustic droplet vaporization) to generate contrast with excellent spatial 
and temporal control. When these agents, commonly referred to as nanodroplets, are formulated 
with cores of low boiling-point perfluo ocarbons such as decaflu orobutane and octafluo opropane, 
they can be activated with low-mechanical index imaging pulses for diagnostic applications. Since 
the utilization of minimum mechanical index is often desirable to avoid unnecessary biological 
effects, enabling consistent activation of these agents in an acoustic fiel is a challenge because the 
energy that must be delivered to achieve the vaporization threshold increases with depth due to 
attenuation. A novel vaporization approach called Activation Pressure Matching has been 
developed to deliver the same pressure throughout a fiel of view in order to produce uniform 
nanodroplet vaporization and to limit the amount of energy that is delivered. In this manuscript, 
we discuss the application of this method with a Versasonics V1 Research Ultrasound System to 
modulate the output pressure from an ATL L11–5 transducer. Vaporization-pulse spacing 
optimization can be used in addition to matching the activation pressure through depth, and we 
demonstrate the feasibility of this approach both in vivo and in vitro. The use of optimized 
vaporization parameters increases the amount of time a single bolus of nanodroplets can generate 
useful contrast and provides consistent image enhancement in vivo. Therefore, APM is a useful 
technique for those wishing to maximize the efficac of phase change contrast agent while 
minimizing delivered acoustic energy.
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I. Introduction
Phase-Change contrast agents (PCCAs) are a unique variant of ultrasound contrast agents 
that can have a longer in vivo circulation time than conventional microbubbles and can be 
formulated to have a distribution in the hundred-nanometer range [1] [5]. This small size 
might allow them to extravasate from the intravascular into the extravascular space in 
regions of leaky endothelium such as that caused by tumor-associated angiogenesis. Low-
boiling point PCCAs have superheated perfluorocarbo (PFC) cores that remain stable in 
vasculature due to increased Laplace pressure and nucleation requirements of the pure 
perfluorocarbo [2], [4] [7]. However, the liquid core of these droplets can be vaporized or 
“activated” with ultrasound to form echogenic microbubbles in a process referred to as 
Acoustic Droplet Vaporization (ADV). Historically, droplets have been used for therapeutic 
applications such as cavitation enhancement and thermal ablation [8] [13], vessel occlusion 
[9], [14], [15], aberration correction [9], [16], drug delivery [17] [19], and more recently, 
MR-guided tumor ablation [20], [21]. ADV can also generate contrast at desired locations 
on demand and the vaporization-generated microbubbles have been evaluated [22] [24] for 
diagnostic applications such as perfusion, molecular imaging, and tumor imaging [1], [25] 
[28]. Much work has been done on the physics of ADV [29] [34] and its dependence on 
acoustic parameters. Recently, droplets have been examined as temperature probes [35]. For 
these purposes, high stability is desired so PFCs with boiling-points close to body 
temperature such as perfluoropentan (PFP) and perfluoroh xane (PFH) are used. Droplet 
vaporization occurs once a pressure threshold is reached and micron-size droplets composed 
of PFCs such as PFP and PFH require vaporization pressures that are above the FDA limit of 
1.9 for diagnostic imaging [2]. However, the use of low boiling point PFCs such as 
decafluoro utane (DFB) and octafluorpropan (OFP) allows for PCCAs to be used with low-
mechanical index (MI) imaging pulses that are under the FDA limit [2], [4], [27], [36].
Creating uniform contrast throughout the target organ is important for obtaining accurate 
measurements of targeting or perfusion and can be challenging due to the energy-sensitive 
activation thresholds of these agents; therefore, optimal activation parameters should be 
used. It is difficul to create the custom pulse sequences necessary for effective PCCA 
vaporization using commercial ultrasound systems because of their lack of programmability. 
Commercial systems have been used for droplet vaporization [27], but this approach relies 
on conventional B-mode pulses for vaporization so there is little spatial control of activation. 
Furthermore, since multiple frames are acquired to generate maximum intensity projections, 
generated microbubbles are interrogated multiple times with high intensity pulses which can 
lead to bubble destruction or cavitation. However, programmable systems such as the 
Verasonics Research Ultrasound System (Verasonics, Kirkland, WA, USA) can be used to 
create unique pulse sequences for droplet vaporization [1], [37]. In this manuscript, we 
describe a pulse optimization approach for generation of uniform PCCA vaporization in a 
region of interest (ROI).
II. Materials and Methods
A Verasonics V1 system driving a 128-element ATL L11–5 linear array transducer has been 
chosen as the example for the optimization of activation parameters discussed here. The 
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imaging scheme that was used to capture contrast generated by droplet activation consisted 
of a plane-wave pulse inversion approach where all 128 elements were fire at the same time 
to deliver a single-cycle, 4.5 MHz unfocused pulse, followed by a second unfocused pulse 
that was 180° out of phase. The receive data from both transmission were added to produce 
a single pulse inversion frame. The transmit beam was steered between ± 18° to acquire data 
from 7 different angles and the resulting frames were averaged and reconstructed using 
Verasonics reconstruction algorithms to form one pulse inversion image. The transducer was 
driven with 10 V and produced a free-fiel Peak-Negative-Pressure (PNP) of 459 kPa. 
Activation was accomplished by using the entire aperture to deliver a series of 5 MHz, 5 
cycle, focused pulses to different locations within a predetermined ROI. One frame was 
captured using the plane-wave pulse inversion pulse sequence both before and after 
activation in order to monitor contrast generation.
A condensation procedure that has previously been described was used to make droplets for 
all in vitro and in vivo experiments from lipid-shelled microbubbles [2], which had the 
following formulation: the lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene-glycol)-2000 
(DSPE-PEG2000) in a 9:1 M ratio and a total lipid concentration of 1.0 mg/mL were 
dissolved in a solution of phosphate-buffered saline (PBS), propylene glycol, and glycerol 
(16:3:1). 1.5 mL of the solution was added to a 3 mL glass vial and the head space was gas-
exchanged with either DFB or OFP. Microbubbles (1–5 μm) were produced by using an 
agitation technique. The microbubble solution was cooled to temperatures ranging between 
−10 °C and −12 °C and condensed by pressurizing the vial with room air.
For all in vitro experiments, a 300 μL volume of the stock droplet solution was injected into 
a water bath at room temperature (22 °C), and a series of focused activation pulses were 
delivered to produce vaporization. Peak rarefactional pressures of 3.75 MPa and 1.5 MPa 
were chosen because they are above the activation thresholds for DFB and OFP [2] [4], [38], 
respectively, for the in vitro experiments which were conducted at room temperature 
(22 °C).
III. Activation Pressure Matching
Since the L11–5 has an elevational lens, the free-fiel pressure for a single applied voltage 
greatly varies with depth, increasing as the elevational focus is approached (Fig. 1a). As a 
result, the amount of vaporization, or the number of droplets that are activated, varies with 
depth in a water bath, as can be seen in the size difference of the generated bubble clouds 
(Fig. 1b). Furthermore, diffraction of focused pulses and a changing F-number, since the 
aperture size is being kept constant, can cause pressure variations in the fiel of view and may 
be additional factors that contribute to the change of vaporization levels with respect to 
depth. Puett et al. described a method for obtaining uniform contrast generation by 
optimizing the spacing between the activation pulses so that individual bubble clouds form a 
larger region that is full of contrast [37]. Although this method accomplishes the goal of 
uniform droplet vaporization in an ROI, it results in over-activation in the deeper regions of 
the fiel of view since the pressure distribution is non-uniform through depth. Consequently, 
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the ROI is insonifie with more energy than is necessary which may be undesirable for 
diagnostic purposes.
The rationale for Activation Pressure Matching (APM) is to deliver pulses with the same 
rarefactional pressure to all activation locations in order to limit the delivered energy. This 
technique not only overcomes the changes in pressure due to the elevational lens, but also 
due to diffraction, a changing F-number, and attenuation in tissue. By varying the output 
voltage, the appropriate acoustic pressure can be delivered at different depths. However, the 
Verasonics system requires hundreds of microseconds to switch between voltages, thus a 
complete activation sequence may take several milliseconds. All of the activation pulses 
should be delivered as quickly as possible to ensure uniform vaporization within a single 
plane, as respiratory motion may alter the imaging plane during in vivo imaging. The 
generated contrast must also be imaged quickly to ensure accurate measurement since the 
bubbles produced by the early activation pulses will begin to be cleared from the imaging 
plane. Fortunately, the Verasonics offers a tool for modulating the amplitude of the output 
waveform: Pulse-Width Modulation (PWM). The system uses a tri-state pulser to generate a 
large variety of waveforms (Fig. 2a–b), so in addition to changing the voltage, the amplitude 
of the generated waveform can be adjusted by modifying the number of clock cycles the 
output is at +volts, ground, and volts. As can be seen in Fig. 2a–b, the square wave for a 
PWM value of 0.6 maintains the high or low voltage value for less time compared to the 
wave for a value of 1 which produces an output pulse having a lower pressure amplitude. 
Therefore, a consistent pressure through depth can be achieved by selecting an appropriate 
voltage and adjusting the PWM parameter. Because this approach does not require multiple 
voltage changes, different pressures can be quickly delivered. An example of the relationship 
between output pressure and PWM value for a given voltage is illustrated in Fig. 2c; the 
output pressure increases as the PWM value increases, with a value of 1 signifying no PWM.
In order to determine the correct voltage and PWM values for a desired activation pressure 
at a specifi depth, the system should be calibrated with a hydrophone. We utilized a needle 
hydrophone (HNA-0400, Onda, Sunnyvale, CA, USA) to calibrate the L11–5 transducer for 
a range of PWM values at various voltages and depths. MATLAB (MathWorks, Natick, MA, 
USA) can then be readily used to calculate an appropriate voltage-PWM combination that 
resulted in the desired pressure for each activation depth. An example of this process is 
shown in Fig. 3. The target pressure is set to 1.5 MPa, and by using 6 V and the PWM values 
shown in the solid gray line, the output pressure can be set to within the target ± 10 % to 
account for measurement error from the hydrophone. Furthermore, as shown in Fig. 3, the 
output pressure at 6 V without PWM is enough to cause vaporization at 0.9 cm but is too 
high in deeper regions and would result in over-activation. When APM is used, the bubble 
clouds produced by the activation pulses are of similar size as a result of the consistent 
activation pressure throughout the fiel of view (Fig. 4a). Conversely, when a single voltage is 
used without PWM, the bubble clouds are vastly different in size, indicating that the 
activation pressure for the deeper regions was excessive since vaporization was achieved 
with a smaller pressure in shallower areas (Fig. 4b). The size of the bubble clouds produced 
by the activation pulses was calculated using a method described previously by Puett et al. 
[37], where the number of pixels with an intensity higher than 1% of the cloud’s brightest 
pixel were counted, and this number was multiplied by the pixel size to get an area 
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measurement (Fig. 4c–d). Each box in the box plot represents the area for the 5 bubble 
clouds at the different depths (rows). The size of the bubble clouds is very similar between 
the different depths when APM is used (Fig 4c); cloud size between the different depths is 
not significan for any two depths. In contrast, when a single voltage is used for activation, 
there is a clear positive trend as the elevational focus is approached, and the area of the 
bubble clouds was significan between rows in all but 3 cases (Fig 4d).
IV. Optimization of activation pulse spacing
In order to produce a uniform area of activation in the ROI, the spacing between the 
activation pulses must be adjusted. Puett et al. described a procedure for optimizing the 
spacing that consisted of activating a group of vertical and horizontal lines, and varying the 
spacing between them until the full-width-half-maximum (FWHM) of the intensity profile 
overlapped [37]. Since APM was not used, the size of the bubble clouds produced by droplet 
vaporization varied with depth. Therefore, individual lateral and axial spacings had to be 
derived for different regions in the fiel of view. In this example, the same procedure 
described by Puett et al. is used, but since APM produces same-sized bubble clouds 
regardless of depth, only one set of lateral and axial spacing needed to be calculated (Fig. 5). 
Contrast lines separated by different distances were created by activating droplets in a water 
bath and intensity profile were generated by averaging the uncompressed image data along 
either the lateral dimension, for calculating the optimal axial spacing, or axially, for 
calculating the optimal lateral spacing. As discussed above, the optimal spacing is define by 
the overlap of the FWHM of the intensity profiles However, too much overlap is not 
desirable since any interaction that may cause cavitation or bubble destruction between an 
activation pulse and a pre-existing bubble cloud. Therefore, the distance between the right 
FWHM point on the left activation line intensity profile and the left FWHM point on the 
right intensity profil should be as close as possible to zero, so the spacing that has the lowest 
distance value between these two points is the optimal spacing. When the 2 intensity profile 
cannot be differentiated, or the FWHM points are not visible, because the spacing is too 
small, the distance value will be given by subtracting twice the mean FWHM of the largest 
spacing (1 mm and 0.75 mm for the axial and lateral cases, respectively) from the FWHM of 
the intensity profile For example, the FWHM distance value for 0.5 mm in Fig 5a will be 
twice the mean FWHM of the intensity profile for the 1mm spacing (0.95 mm), subtracted 
from the FWHM of the 0.5 mm intensity profil (0.475 mm), which produces a value −0.475 
mm. Three trials were averaged for each spacing, and the FWHM distances for the axial 
spacings 1, 0.75, and 0.5 mm were 0.515 ± 0.13, 0.16 ± 0.034, and −0.475 ± 0.11 mm, 
respectively, and the values for the lateral spacings 0.75, 0.5, 0.25 mm were 0.4 ± 0.089, 
0.22 ± 0.056, and −0.36 ± 0.08 mm, respectively. Therefore, the optimal spacing for the 
L11–5 is around 0.75 mm and 0.5 mm in the axial and lateral directions, respectively. Using 
APM along with the optimized spacing, a uniform region of vaporization can be generated 
(Fig. 6). As previously discussed, uniform activation is possible without APM using the 
methods described by Puett et al. [37]. However, that approach requires over-activation of 
droplets around the elevational focus in order to vaporize regions located further away from 
the transducer. APM creates uniform vaporization without excessive vaporization or energy 
delivery in the near-field
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V. In Vivo Demonstration of apm
APM can be easily translated to in vivo applications. The previously described procedure 
can be applied in vivo with attenuation compensation. Here, we demonstrate the 
effectiveness of APM in rat kidneys. As with in vitro activation, an appropriate PWM value 
must be selected for each depth for a specifi voltage. However, the target pressure will not be 
fla through depth but rather, it will increase so that the same pressure is delivered to all the 
activation locations after it is attenuated by tissue (Fig. 7). In order to calculate the required 
initial pressure before attenuation, the free-fiel pressure at each depth is derated using the 
following model: 3.5 mm of superficia tissue (α ==0.6 dB/MHz/cm) followed by kidney 
tissue (α = 1 dB/MHz/cm), assuming a kidney frequency dependence of 1.1 (α = α0f1.1) 
[39], [40]. Similar to the in vitro case, APM can yield a pressure through depth that is within 
± 10% of the target pressure by selecting the appropriate attenuation model and PWM values 
for the different depths while using the same voltage (8 V). Additionally, not using APM 
would result in over-activation in the shallower regions since 8 V produces a pressure that is 
higher than the target without PWM.
Using the attenuation-corrected APM method with the optimized activation pulse spacing 
discussed earlier, OFP droplets were activated in a rat kidney (Fig. 8). A custom MATLAB 
script was used to manually segment the kidney and calculate the locations of the activation 
pulses and their appropriate PWM values. Activation locations start with the deepest lines 
firs in order to avoid attenuation of the subsequent pulses by the generated contrast, as 
indicated by the red dashed lines. APM generates uniform vaporization inside the kidney, 
indicating that the pressure delivered to each activation location was similar, and the spacing 
between locations was appropriate.
VI. In Vivo benefit of apm
Efficien activation of PCCAs is important not only for depositing the minimum amount of 
energy necessary to cause PCCA activation, but also for improving the contrast enhancement 
generated over time in order to reduce contrast agent dose. In a previous study using un-
optimized vaporization parameters, the circulation half-life of DFB and OFP droplets in rats 
was estimated at 11 and 3.5 minutes, respectively [1]. In this previous study, droplets 
injected in a bolus were activated using the same parameters over a period of 19 minutes and 
the generated contrast enhancement at all time points was fitte to a mono-exponential to 
obtain the circulation half-life. In this study, the same procedure is followed except that 
APM was used for vaporization at the DFB threshold (3.5 MPa). Briefl, a bolus consisting of 
60 μL droplets (around 1×109 droplets) diluted in 60 μL of saline was injected and a series 
of activation pulses was delivered every 3 minutes for 19 minutes, starting 1 minute after 
injection. Optimized spacing was not used in order to reduce over-activation of OFP, as it is 
much more volatile than DFB. As expected, OFP yielded a higher contrast enhancement 
with more droplets activated for a given pulse (Fig. 9). However, the decreased stability of 
OFP leads to spontaneous vaporization which reduces the concentration of agents in droplet 
form and decreases the circulation time [1]. It should be clarifie that what is being referred 
to as “circulation time” in this study is the time for which detectable contrast can be 
generated, not the time the droplets remain in the vasculature. Fig. 9 shows that the contrast 
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enhancement, in dB, relative to a baseline image taken prior to the injection of PCCAs. The 
Contrast enhancement for OFP is almost three times that of DFB (a) at the one-minute time 
point, and OFP is cleared much faster than DFB (b). The contrast enhancement at each time-
point is normalized to the one-minute time point and fitte to a mono-exponential decay 
model in order to calculate the circulation half-life. The half-life for DFB and OFP was 
15.97 ± 3.0 and 6.92 ± 0.7 min, respectively. In both cases, the resulting value obtained by 
using APM was substantially higher than previously reported. The droplets are circulating 
the same amount of time, but using APM makes the vaporization at all depths more efficien 
enabling the use of the injected droplets for a much longer time. This part of the study 
demonstrates the benefi of using optimized activation parameters for in vivo applications.
VII. Conclusion
The purpose of this manuscript is to present a novel approach for optimizing activation 
parameters for PCCA vaporization. Activation Pressure Matching, the method described in 
this study, relies on using PWM to regulate the output pressure so that all activation 
locations are insonifie with the same amount of pressure. The use of this approach allows for 
efficien droplet vaporization and the generation of uniform contrast in a region of interest 
without delivery of excessive pressure. In addition to modulating the output pressure for 
different depths, optimal spacing between activation points can be found in order to 
consistently vaporize droplets in the target. APM can be applied in vivo by using an 
appropriate attenuation model. In this study a rat kidney model was used to demonstrate that 
by modulating the initial output pressure, uniform vaporization is achieved in the tissue after 
attenuation compensation. When APM was used to activate OFP and DFB droplets over 
time, it was found that the circulation time of both compounds was much longer than 
indicated by previous experiments that used un-optimized activation parameters because 
higher amounts of detectable contrast are generated.
This study has presented a new method for activating droplets that can be a valuable tool for 
PCCA applications for the treatment and assessment of disease. For example, if droplets are 
targeted to a disease marker, it is imperative that the vaporization pressure is consistent 
throughout the tissue since variations in activation pressure will cause spatial 
inhomogeneities in vaporization. This is an issue because it would be challenging to 
determine if differences in contrast are a result of inconsistent pressures or different levels of 
targeting throughout the tissue.
Inconsistent activation pressure would also be a problem for a perfusion imaging approach 
using PCCAs. Instead of measuring the wash-in of contrast into an imaging plane, as is done 
in microbubble destruction reperfusion techniques, the contrast generated by droplet 
activation can be monitored as it washes out of the imaging plane to obtain a measure of 
perfusion. Because droplets provide excellent temporal and spatial control of contrast 
generation, different regions of a target can be activated at different times in order to see any 
differences in perfusion in different tissues. A previous study found that the perfusion rate in 
kidneys depends on the concentration of microbubbles that is used [41]. Therefore, if 
different vaporization pressures are used, the perfusion rates might be different due to a 
disparity in droplet activation and not due to any physiological factors.
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Additionally, when investigating bio-effects caused by droplet vaporization, it is essential to 
produce uniform vaporization in order to reliably correlate droplet vaporization with 
therapeutic effects or tissue damage. Also, it is reasonable to assume that limiting the 
amount of energy delivered into the tissue to the minimum needed to achieve the desired 
result will induce the least amount of bioeffects. These needs suggest that APM will be a 
desirable tool in not only imaging but also therapeutic applications.
APM can vaporize droplets efficientl to produce uniform contrast generation in rat kidneys. 
However, APM does not take into account phenomena such as aberration which is a 
significan factor in human ultrasound imaging. As a result of aberration, pulses become de-
focused by changes in density and speed of sound between different tissues. De-focusing of 
activation pulses can result in uneven vaporization of PCCAs and may require the tissue to 
be insonifie with increased energy to overcome the loss of pressure due to weaker focusing. 
Therefore, a simple attenuation model may not be appropriate for use in humans where the 
volume of tissue that is interrogated is much larger than in a rat or mouse. Interestingly, 
using droplets for aberration correction has been proposed [9], so it is possible that 
preliminary pulses can be delivered to form microbubbles and monitor vaporization 
differences in order to evaluate aberration effects and further calibrate APM for efficien 
activation. Additionally, APM depends heavily on using the correct attenuation model and 
therefore, a different derating scheme must be used for each type of tissue (various types of 
tumors and body organs) in order to efficientl obtain uniform droplet activation.
APM is a novel approach to PCCA activation that has various advantages over prior 
methods; mainly, the ability to deliver the same amount of pressure to all activation sites in 
order to minimize the energy that is delivered and produce uniform activation throughout the 
target. Furthermore, APM can serve as an important tool for the accurate assessment of 
disease progression and response to therapy.
Acknowledgments
The research presented here was funded in part by the National Institute of Health (1F31CA196216-01) and 
Focused Ultrasound Foundation. We would like to thank Dr. Paul Sheeran and Connor Puett for developing the 
techniques upon which this work was built.
References
1. Sheeran PS, Rojas JD, Puett C, Hjelmquist J, Arena CB, Dayton PA. Contrast-Enhanced Ultrasound 
Imaging and in vivo Circulatory Kinetics with Low-Boiling-Point Nanoscale Phase-Change 
Perfluorocarbo Agents. Ultrasound Med Biol. Mar; 2015 41(3):814–31. [PubMed: 25619781] 
2. Sheeran PS, Luois SH, Mullin LB, Matsunaga TO, Dayton PA. Design of ultrasonically-activatable 
nanoparticles using low boiling point perfluorocarbons. Biomaterials. Apr; 2012 33(11):3262–9. 
[PubMed: 22289265] 
3. Sheeran PS, Luois S, Dayton PA, Matsunaga TO. Formulation and acoustic studies of a new phase-
shift agent for diagnostic and therapeutic ultrasound. Langmuir. Sep; 2011 27(17):10412–20. 
[PubMed: 21744860] 
4. Sheeran PS, Dayton PA. Phase-change contrast agents for imaging and therapy. Curr Pharm Des. 
Jan; 2012 18(15):2152–65. [PubMed: 22352770] 
5. Mountford PA, Thomas AN, Borden MA. Thermal Activation of Superheated Lipid-Coated 
Perfluorocarbo Drops. Langmuir. 2015 p. 150408150628001. 
Rojas and Dayton Page 8
IEEE Trans Ultrason Ferroelectr Freq Control. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6. Sheeran PS, Matsunaga TO, Dayton PA. Phase change events of volatile liquid perfluorocarbo 
contrast agents produce unique acoustic signatures. Phys Med Biol. Jan; 2014 59(2):379–401. 
[PubMed: 24351961] 
7. Dove JD, Mountford PA, Murray TW, Borden Ma. Engineering optically triggered droplets for 
photoacoustic imaging and therapy. Biomed Opt Express. 2014; 5(12):4417. [PubMed: 25574448] 
8. Miller DL, Kripfgans OD, Carson PL. Cavitation nucleation agents for nonthermal ultrasound 
therapy. J Acoust Soc Am. 2000; 107(6):3480–3486. [PubMed: 10875392] 
9. Kripfgans OD, Fowlkes JB, Woydt M, Eldevik OP, Carson PL. in vivo droplet vaporization for 
occlusion therapy and phase aberration correction. IEEE Trans Ultrason Ferroelectr Freq Control. 
2002; 49(6):726–738. [PubMed: 12075966] 
10. Zhang P, Porter T. An in vitro study of a phase-shift nanoemulsion: a potential nucleation agent for 
bubble-enhanced HIFU tumor ablation. Ultrasound Med Biol. Nov; 2010 36(11):1856–66. 
[PubMed: 20888685] 
11. Samuel S, Duprey A, Fabiilli ML, Bull JL, Brian Fowlkes J. in vivo Microscopy of Targeted Vessel 
Occlusion Employing Acoustic Droplet Vaporization. Microcirculation. 2012; 19(6):501–509. 
[PubMed: 22404846] 
12. Kripfgans OD, Zhang M, Fabiilli ML, Carson PL, Padilla F, Swanson SD, Mougenot C, Fowlkes 
JB. Acceleration of ultrasound thermal therapy by patterned acoustic droplet vaporization. J 
Acoust Soc Am. 2014; 135(January 2014):537–44. [PubMed: 24437794] 
13. Zhu M, Jiang L, Fabiilli ML, Zhang A, Fowlkes JB, Xu LX. Treatment of murine tumors using 
acoustic droplet vaporization-enhanced high intensity focused ultrasound. Phys Med Biol. 2013; 
58(17):6179. [PubMed: 23948709] 
14. Zhang M, Fabiilli ML, Haworth KJ, Fowlkes JB, Kripfgans OD, Roberts WW, Ives KA, Carson 
PL. Initial Investigation of Acoustic Droplet Vaporization for Occlusion in Canine Kidney. 
Ultrasound Med Biol. 2010; 36(10):1691–1703. [PubMed: 20800939] 
15. Kripfgans OD, Orifici CM, Carson PL, Ives KA, Eldevik OP, Fowlkes JB. Acoustic droplet 
vaporization for temporal and spatial control of tissue occlusion: A kidney study. IEEE Trans 
Ultrason Ferroelectr Freq Control. 2005; 52(7):1101–1108. [PubMed: 16212249] 
16. Haworth KJ, Fowlkes JB, Carson PL, Kripfgans OD. Towards Aberration Correction of 
Transcranial Ultrasound Using Acoustic Droplet Vaporization. Ultrasound Med Biol. 2008; 34(3):
435–445. [PubMed: 17935872] 
17. Rapoport N, Nam KH, Gupta R, Gao Z, Mohan P, Payne A, Todd N, Liu X, Kim T, Shea J, Scaife 
C, Parker DL, Jeong EK, Kennedy AM. Ultrasound-mediated tumor imaging and nanotherapy 
using drug loaded, block copolymer stabilized perfluorocarbo nanoemulsions. J Control Release. 
Jul; 2011 153(1):4–15. [PubMed: 21277919] 
18. Fabiilli ML, Haworth KJ, Sebastian IE, Kripfgans OD, Carson PL, Fowlkes JB. Delivery of 
chlorambucil using an acoustically-triggered perfluoropentan emulsion. Ultrasound Med Biol. 
2010; 36(8):1364–1375. [PubMed: 20691925] 
19. Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam KH. Controlled and targeted tumor 
chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release. Sep; 2009 
138(3):268–76. [PubMed: 19477208] 
20. Phillips LC, Puett C, Sheeran PS, Wilson Miller G, Matsunaga TO, Dayton PA. Phase-shift 
perfluorocarbo agents enhance high intensity focused ultrasound thermal delivery with reduced 
near-fiel heating. J Acoust Soc Am. 2013; 134(2):1473–1482. [PubMed: 23927187] 
21. Kopechek JA, Park E, Mei C, McDannold NJ, Porter TM. Accumulation of phase-shift 
nanoemulsions to enhance MR-guided ultrasound-mediated tumor ablation in vivo. J Heal Eng. 
2013; 4:109–284.
22. Reznik N, Shpak O, Gelderblom EC, Williams R, De Jong N, Versluis M, Burns PN. The efficien y 
and stability of bubble formation by acoustic vaporization of submicron perfluorocarbo droplets. 
Ultrasonics. 2013; 53(7):1368–1376. [PubMed: 23652262] 
23. Reznik N, Lajoinie G, Shpak O, Gelderblom EC, Williams R, de Jong N, Versluis M, Burns PN. 
On the acoustic properties of vaporized submicron perfluorocarbo droplets. Ultrasound Med Biol. 
2014; 40(6):1379–1384. [PubMed: 24462162] 
Rojas and Dayton Page 9
IEEE Trans Ultrason Ferroelectr Freq Control. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
24. Reznik N, Seo M, Williams R, Bolewska-Pedyczak E, Lee M, Matsuura N, Gariepy J, Foster FS, 
Burns PN. Optical studies of vaporization and stability of fluorescentl labelled perfluorocarbo 
droplets. Phys Med Biol. 2012; 57(21):7205–17. [PubMed: 23060210] 
25. Sheeran PS, Streeter JE, Mullin LB, Matsunaga TO, Dayton PA. Toward ultrasound molecular 
imaging with phase-change contrast agents: an in vitro proof of principle. Ultrasound Med Biol. 
May; 2013 39(5):893–902. [PubMed: 23453380] 
26. Williams R, Wright C, Cherin E, Reznik N, Lee M, Gorelikov I, Foster FS, Matsuura N, Burns PN. 
Characterization of Submicron Phase-change Perfluorocarbo Droplets for Extravascular 
Ultrasound Imaging of Cancer. Ultrasound Med Biol. 2013; 39(3):475–489. [PubMed: 23312960] 
27. Sheeran PS, Yoo K, Williams R, Daghighi Y, Cherin E. Image-guided characterization of phase-
shift droplets at pre-clinical frequencies in vitro and in vivo. IEEE Int Ultrason Symp Proceedings, 
IUS. 2015
28. Porter TR, Arena C, Sayyed S, Lof J, High RR, Xie F, Dayton PA. Targeted transthoracic acoustic 
activation of systemically administered nanodroplets to detect myocardial perfusion abnormalities. 
Circ Cardiovasc Imaging. 2016; 9(1):1–9.
29. Kripfgans OD, Fabiilli ML, Carson PL, Fowlkes JB. On the acoustic vaporization of micrometer-
sized droplets. J Acoust Soc Am. 2004; 116(1):272–281. [PubMed: 15295987] 
30. Qamar A, Wong ZZ, Fowlkes JB, Bull JL. Dynamics of acoustic droplet vaporization in gas 
embolotherapy. Appl Phys Lett. 2010; 96:14.
31. Shpak O, Verweij M, Vos HJ, de Jong N, Lohse D, Versluis M. Acoustic droplet vaporization is 
initiated by superharmonic focusing. Proc Natl Acad Sci U S A. 2014; 111(5):1697–702. 
[PubMed: 24449879] 
32. Li DS, Kripfgans OD, Fabiilli ML, Brian Fowlkes J, Bull JL. Initial nucleation site formation due 
to acoustic droplet vaporization. Appl Phys Lett. 2014; 104(6):6–10.
33. Fabiilli ML, Member S, Haworth KJ, Fakhri NH, Kripfgans OD, Carson PL, Fowlkes JB, Member 
A. The Role of Inertial Cavitation in Acoustic Droplet Vaporization. IEEE Trans Ultrason 
Ferroelectr Freq Control. 2009; 56(5):1006–1017. [PubMed: 19473917] 
34. Droplet A, For V, Applications D. Acoustic Droplet Vaporization for Therapeutic and Diagnostic 
Applications. Ultrasound Med Biol. 2000; 26(7):1177–1189. [PubMed: 11053753] 
35. Mountford PA, Smith WS, Borden MA. Fluorocarbon Nanodrops as Acoustic Temperature Probes. 
Langmuir. 2015 p. 150911170424004. 
36. Sheeran PS, Wong VP, Luois S, McFarland RJ, Ross WD, Feingold S, Matsunaga TO, Dayton PA. 
Decafluoro utane as a phase-change contrast agent for low-energy extravascular ultrasonic 
imaging. Ultrasound Med Biol. Sep; 2011 37(9):1518–30. [PubMed: 21775049] 
37. Puett C, Sheeran PS, Rojas JD, Dayton PA. Pulse sequences for uniform perfluorocarbo droplet 
vaporization and ultrasound imaging. Ultrasonics. 2014; 54(7):2024–2033. [PubMed: 24965563] 
38. Matsunaga TO, Sheeran PS, Luois S, Streeter JE, Mullin LB, Banerjee B, Dayton PA. Phase-
change nanoparticles using highly volatile perfluorocarbons toward a platform for extravascular 
ultrasound imaging. Theranostics. Jan; 2012 2(12):1185–98. [PubMed: 23382775] 
39. Cobbold, RSC. Foundations of Biomedical Ultrasound. New York: Oxford University Press; 2007. 
40. Hill, CR., Bamber, J., ter Haar, G. Physical Principles of Medical Ultrasonics. 2. Wiley; 2004. 
41. Feingold S, Gessner R, Guracar IM, Dayton PA. Quantitative Volumetric Perfusion Mapping of 
The Microvasculature Using Contrast Ultrasound. Invest Radiol. 2010; 45(10)
Rojas and Dayton Page 10
IEEE Trans Ultrason Ferroelectr Freq Control. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Biographies
Juan D. Rojas (S’14) obtained his B.S. degree in biomedical engineering from the 
University of North Carolina in 2012. He joined the Dayton lab in 2013 and is pursuing a 
Ph.D. from the University of North Carolina and North Carolina State University Joint 
Department of Biomedical Engineering. His research includes the development of 
technologies for the use of phase change contrast agents to assess disease progression and 
evaluate response to therapy.
Paul A. Dayton received his B.S. degree in physics from Villanova University in 1995, his 
M.E. degree in electrical engineering from the University of Virginia in 1998, and his Ph.D. 
degree in biomedical engineering in 2001, also from the University of Virginia. He pursued 
postdoctoral research and was later research faculty at the University of California, Davis. 
Much of Dr. Dayton’s training was under the mentorship of Dr. Katherine Ferrara; his initial 
studies involved high-speed optical and acoustical analysis of individual contrast agent 
microbubbles. In 2007, Dr. Dayton moved to the Joint Department of Biomedical 
Engineering at UNC Chapel Hill and NC State University, Raleigh, where he is now 
Professor and Associate Department Chair. Dr. Dayton is currently Associate Director for 
Education for the Biomedical Imaging Research Center, and his research interests involve 
ultrasound contrast imaging, ultrasound-mediated therapies, and medical devices. Dr. 
Dayton is a member of the technical program committee for the IEEE UFFC Society, and a 
member of the editorial boards for the journals IEEE Transactions on Ultrasonics, 
Ferroelectrics, and Frequency Control; Molecular Imaging; and Bubble Science, 
Engineering, and Technology.
Rojas and Dayton Page 11
IEEE Trans Ultrason Ferroelectr Freq Control. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Several activation pulses were delivered to the locations indicated by the green markers in 
order to activate OFP droplets in a water bath. Output pressure varies with depth in a water 
bath for a single voltage as a result of the elevational lens on the L11–5 (a). This change in 
pressure leads to different levels of droplet activation (b). The pressure increases as the 1.4 
cm elevational focus is approached, causing the bubble clouds produced by vaporization to 
be larger.
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Fig. 2. 
The Verasonics system uses PWM to modulate the amplitude of the output waveform by 
changing the time the output is at each of the three voltage states (+V, −V, ground). As can 
be seen in (a), the width of each square cycle is narrower for the PWM of 0.6 (gray line) 
than for the PWM value of 1 (black line), and this difference produces waveforms of 
different amplitudes (b). (c) demonstrates that decreasing the PWM value from 1 (no PWM) 
produces a waveform with a lower peak negative pressure. Therefore, a range in pressures 
can be achieved using only 1 peak-to-peak voltage.
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Fig. 3. 
In this example of the APM process, a target activation pressure of 1.5 MPa (solid black) is 
chosen, and the PWM values (solid gray) are applied to 6 V to obtain an output pressure 
(dashed black) that is within ± 10% (light dashed) of the target pressure for depths ranging 
from 0.9 to 1.7 cm.
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Fig. 4. 
Difference between using APM (a) and a single voltage without PWM (b). The bubble 
clouds on (a) are similar in size, indicating that the vaporization pressure was uniform for all 
activation areas. Not using PWM results in a range of activation pressures that vary with 
depth, which increases contrast generation as the pulses approach the elevational focus. The 
area of the activation clouds was measured for each depth (rows) and APM produced bubble 
clouds of the same size (c), while the size of the clouds increased with depth when a single 
voltage was used (d).
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Fig. 5. 
Intensity profile (rows a and c) were generated by averaging imaged data from activation 
lines (rows b and d) separated by a range of distances between 0.25 and 1 mm. The optimal 
spacing between activation lines is characterized by the overlap of the FWHM of the 
intensity profile of adjacent lines and so 0.75 mm and 0.5 mm are the best axial and lateral 
spacing.
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Fig. 6. 
APM and optimized spacing creates a region of uniform contrast.
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Fig. 7. 
Pressure map with distance after accounting for attenuation using a rat kidney attenuation 
model. The target pressure (solid back) of 1.5 MPa increases with depth since the initial 
pressure will be derated by the tissue. Using APM with the PWM values shown in the solid 
gray curve, the pressure delivered to each depth is within ±10% of the target pressure 
(dashed black line). The output generated without APM (dotted black) is higher than the 
target and would result in the delivery of higher pressure than is necessary for droplet 
vaporization.
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Fig. 8. 
OFP droplet activation in a rat kidney using APM and optimized spacing. The left image 
shows the contrast image of the kidney before droplet vaporization, and the image on the 
right is an image of the post-activation contrast that was generated by the activation pulses 
(center). The green dots on the center image represent the activation locations. Consistent 
activation throughout the kidney was achieved by sending activation pulses with the same 
peak rarefactional pressure regardless of depth.
Rojas and Dayton Page 19
IEEE Trans Ultrason Ferroelectr Freq Control. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 9. 
Contrast enhancement over the baseline case for each time point (a), and normalized to the 
one-minute time-point (b). The plot on the left shows that the contrast generated when OFP 
droplets were activated using APM is much greater than that of DFB at the one-minute time 
point. Conversely, OFP has a circulation time that is less than that of DFB, as can be seen on 
the right plot. A mono-exponential (Ae−bt) was f t to the normalized contrast enhancement 
data (solid line) and used to compute the circulation half-life for each type of droplet. The 
dashed lines represent the 95% confidenc intervals of the fit The half-life was 15.97 ± 2.96 
min for DFB and 6.92 ± 0.65 min for OFP. Both values are much higher than previously 
reported.
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